The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11152 malaria professionals are enjoying the free benefits of MalariaWorld today

ruxolitinib

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults

November 3, 2021 - 20:27 -- Open Access
Author(s): 
Chughlay MF, Barnes KI, Chalon S, et al.
Reference: 
Antimicrob Agents Chemother. 2021 Oct 25:AAC0158421

Despite repeated malaria infection, individuals living in malaria endemic areas remain vulnerable to re-infection. The Janus kinase (JAK1/2) inhibitor ruxolitinib could potentially disrupt the parasite-induced dysfunctional immune response when administered with anti-malarial therapy. This randomized, single-blind, placebo-controlled, single center phase 1 trial investigated the safety, tolerability, pharmacokinetic and pharmacodynamic profile of ruxolitinib and the approved antimalarial artemether-lumefantrine in combination.

Falciparum malaria-induced secondary hemophagocytic lymphohistiocytosis successfully treated with ruxolitinib

August 11, 2020 - 07:48 -- Open Access
Author(s): 
Fuchs A, Orth HM, Germing U, Kondakci M, Holtfreter M, Feldt T, Jensen BE, Häussinger D
Reference: 
Int J Infect Dis. 2020 Aug 7:S1201-9712(20)30626-3

JAK/STAT-signaling plays a major role in the pathogenesis of secondary hemophagocytic lymphohistiocytosis.

Subscribe to RSS - ruxolitinib